antibodies -online.com





anti-CYP2A13 antibody (AA 301-400)



Image



Go to Product page

()	11/0	r\ /1	$\triangle 1 $
	$\lor \lor \vdash$	$I \vee I$	ew

Quantity:	100 μL	
Target:	CYP2A13	
Binding Specificity:	AA 301-400	
Reactivity:	Human	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This CYP2A13 antibody is un-conjugated	
Application:	Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))	

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human CYP2A13
Isotype:	IgG
Cross-Reactivity:	Human
Purification:	Purified by Protein A.

Target Details

Target:	CYP2A13
Alternative Name:	CYP2A13 (CYP2A13 Products)

Target Details

Background:	Synonyms: Cytochrome P450 2A13, CYP2A13, CYPIIA13, CYP2A13	
	Background: Exhibits a coumarin 7-hydroxylase activity. Active in the metabolic activation of	
	hexamethylphosphoramide, N,N-dimethylaniline, 2'-methoxyacetophenone, N-	
	nitrosomethylphenylamine, and the tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-	
	pyridyl)-1-butanone. Possesses phenacetin O-deethylation activity.	
Gene ID:	1553	
UniProt:	Q16696	

Application Details

	11 (100) 1.00 200
	IF(ICC) 1:50-200
	IF(IHC-F) 1:50-200
	IF(IHC-P) 1:50-200
	IHC-F 1:100-500
	IHC-P 1:200-400
	ELISA 1:500-1000
Application Notes:	WB 1:300-5000

Handling

Format:	Liquid	
Concentration:	1 μg/μL	
Buffer:	0.01M TBS(pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.	
Preservative:	ProClin	
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.	
Storage:	4 °C,-20 °C	
Storage Comment:	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.	
Expiry Date:	12 months	




Image 1. Hcclm3 lysates probed with CYP2A13 Polyclonal Antibody, Unconjugated at 1:300 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37°C.